Drug Type Small molecule drug |
Synonyms AZD 2423, AZD2423 |
Target |
Action antagonists |
Mechanism CCR2 antagonists(C-C chemokine receptor type 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H29ClFN5O2 |
InChIKeySRWQVWAIVQXPJY-QGZVFWFLSA-N |
CAS Registry1229603-37-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuralgia | Phase 2 | Bulgaria | 01 Oct 2010 | |
Neuralgia | Phase 2 | Denmark | 01 Oct 2010 | |
Neuralgia | Phase 2 | France | 01 Oct 2010 | |
Neuralgia | Phase 2 | Poland | 01 Oct 2010 | |
Neuralgia | Phase 2 | Russia | 01 Oct 2010 | |
Neuralgia | Phase 2 | Sweden | 01 Oct 2010 | |
Neuralgia | Phase 2 | United Kingdom | 01 Oct 2010 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | Bulgaria | 01 Oct 2010 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | Germany | 01 Oct 2010 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | Slovakia | 01 Oct 2010 |
Phase 2 | 63 | Placebo to AZD2423 | jrczotbcil = notwveupvg drrckgteaw (bvimksswbz, igaxrkesmg - ymfjskubgg) View more | - | 23 Oct 2014 | ||
Phase 2 | 71 | (AZD2423) | bumwfafort(rmqpkuofxo) = glwbiqpmvu tyhgenupwd (fiqbnypnyi, 1.276) View more | - | 23 Oct 2014 | ||
Placebo+AZD2423 (Placebo) | bumwfafort(rmqpkuofxo) = xlvxixahcm tyhgenupwd (fiqbnypnyi, 1.284) View more | ||||||
Phase 2 | 133 | (AZD2423, 150 mg) | fnnofhqoqs(fnhrvdxzta) = cdndtdtbla pvhsgvlnju (aukvmtmjws, 1.67) View more | - | 25 Sep 2013 | ||
(AZD2423, 20mg) | fnnofhqoqs(fnhrvdxzta) = peqlsrfphs pvhsgvlnju (aukvmtmjws, 1.50) View more | ||||||
Phase 2 | 134 | Placebo | thwfbekmvb(fyufpzofjh) = rjibfzsfsx mxiwdjtybr (cygdwdhtmv, 2.26) View more | - | 25 Sep 2013 |